Ipsen snags an approved cancer drug in $247M M&A deal as another battered biotech sells cheap - Endpoints News

You can add Paris-based Ipsen to the list of discount buyers patrolling the penny stock pack for a cheap M&A deal. The French biotech, which has had plenty of its own problems to grapple with, has swooped in to buy Epizyme $EPZM for $247 million in cash and a…

As more than a dozen states are now readying so-called “trigger” laws to kick into effect immediate abortion bans following the overturning of Roe v. Wade on Friday, these laws, in the works for more… [+773 chars]

full article...